All In Biotech

Drug Trial Radar · NCT07414524

VLA1553-403 Pregnancy Surveillance Study

Observational Study to Evaluate the Safety of Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Pregnant Women Exposed to the Vaccine in Brazil

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 11, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Valneva Austria GmbHIndustry
Sponsor type
Industry
Collaborators
Butantan Foundation; Coalition for Epidemic Preparedness Innovations
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last menstrual period. A matched comparator cohort of pregnant women vaccinated with routine, pregnancy-recommended vaccines (not exposed to VLA1553) is included. No study procedures beyond routine care are performed.

Conditions

  • Chikungunya Virus Infection

Interventions

  • Live-attenuated CHIKV vaccine VLA1553Biological

    Non-interventional study: VLA1553 is used in the pilot vaccination strategy which will start along with this observational study.

  • Vaccine(s) approved for use during pregnancy by the MoHBiological

    Vaccine(s) approved for use during pregnancy by the MoH

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency (n,%) of individuals with any outcome (pregnancy and infant health), as described in the protocol.Time frame: Study start through study completion, an average of 12 months
  2. Frequency (n,%) of specific outcomes (pregnancy and infant health), as described in the protocol.Time frame: Study start through study completion, an average of 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras

    Belo Horizonte, Minas Gerais, Brazil

  • Fundação Faculdade Regional De Medicina De São José Do Rio Preto

    São Pedro, São Paulo, Brazil

  • Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus

    Laranjeiras, Sergipe, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.